KMYY(SH:600518) Jing Ji Guan Cha Wang·2026-02-15 01:32Group 1 - The company has completed the implementation of the capital reserve transfer to increase share capital as part of its restructuring plan, with 4.145 billion shares registered and 6.5 billion yuan of restructuring funds paid in full [1] - The company is executing a compensation of 2.459 billion yuan to over 50,000 investors due to a securities false statement case, with compensation methods including cash, stocks, and trust income rights [2] - The company has initiated litigation against the former management and related responsible parties, with the case currently under court review [3] Group 2 - The company reported a revenue of 3.96 billion yuan and a net profit attributable to shareholders of 13 million yuan for the first three quarters of 2025, representing a year-on-year increase of 160.84% [4] - The company emphasizes traditional Chinese medicine as its core business, operating eight production bases and a "smart pharmacy" model, with over 600 intellectual property rights accumulated by mid-2025 [5]